|
|
|
|
|
by sxg
1716 days ago
|
|
With the segmentations these models create, you can create reports that quantitatively describe the changes in different tumor tissues. That info can be useful for guiding chemotherapy and radiotherapy decisions. Currently, the accepted practice is to report these changes qualitatively without using segmentations (the way it’s been done for years). While the segmentations created by the models are probably good enough to use in practice today, the logistical challenges of integrating the model with the clinical workflow impede its actual use. Sure, you could manually export your brain MR to run the model, but that’s a pain to do when you’re reading ~25 brain MR cases/day. |
|
(I know nothing of this tbh, except I once had a demo of a radiologist back when the gamma knife was introduced, have a colleague who became a radiotherapist and a friend who works in ML for Philips medical.)